KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 50 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $701,415 | +110533.3% | 77,935 | -3.4% | 0.00% | – |
| Q1 2023 | $634 | -83.7% | 80,703 | -86.0% | 0.00% | -100.0% |
| Q4 2022 | $3,895 | -99.9% | 576,251 | +20.6% | 0.00% | -50.0% |
| Q3 2022 | $6,935,000 | +602.6% | 477,958 | +376.4% | 0.00% | +300.0% |
| Q2 2022 | $987,000 | +290.1% | 100,317 | +485.0% | 0.00% | – |
| Q1 2022 | $253,000 | -60.5% | 17,148 | -53.3% | 0.00% | – |
| Q3 2021 | $641,000 | +17.2% | 36,715 | +27.5% | 0.00% | – |
| Q4 2020 | $547,000 | -30.8% | 28,797 | -54.1% | 0.00% | -100.0% |
| Q3 2020 | $790,000 | +37.6% | 62,778 | +32.3% | 0.00% | 0.0% |
| Q2 2020 | $574,000 | +14.6% | 47,462 | +68.6% | 0.00% | 0.0% |
| Q4 2019 | $501,000 | +205.5% | 28,148 | +98.0% | 0.00% | – |
| Q3 2019 | $164,000 | -25.1% | 14,219 | +43.7% | 0.00% | – |
| Q2 2019 | $219,000 | -92.1% | 9,895 | -89.7% | 0.00% | -100.0% |
| Q1 2019 | $2,761,000 | +139.9% | 96,470 | +85.4% | 0.00% | +300.0% |
| Q3 2018 | $1,151,000 | +975.7% | 52,041 | +296.7% | 0.00% | – |
| Q2 2018 | $107,000 | -95.1% | 13,117 | -94.3% | 0.00% | -100.0% |
| Q1 2018 | $2,173,000 | -5.8% | 229,248 | -3.1% | 0.00% | 0.0% |
| Q4 2017 | $2,307,000 | – | 236,584 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |